Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with Chronic Lymphocytic Leukaemia (CLL) or Small Lymphocytic Lymphoma (SLL), confirmed by specific blood cell counts or imaging findings.
• People who are currently being treated with a type of targeted therapy called a BTK inhibitor (such as ibrutinib, acalabrutinib, or zanubrutinib) for at least six months, at a stable dose for at least the past three months.
• People aged 18 years or older.
• People with a general health status rated as reasonably functional (ECOG performance status 0–2, meaning able to carry out normal or light activity — confirm with trial site).
• People whose CLL/SLL can still be detected in blood tests or on imaging scans during the screening period.
• People considered "low risk" for a serious side effect called tumour lysis syndrome, meaning all lymph nodes are smaller than 5 cm and blood lymphocyte counts are below a certain level, confirmed within 30 days of enrolment.
• People whose blood test results meet minimum levels for white blood cells, platelets, kidney function, and liver function (specific thresholds apply — confirm with trial site).
• People who are able to swallow oral (tablet/capsule) medications and do not have conditions that seriously affect the absorption of food or medication in the gut.
• People who are able to take a specific medication to help protect the kidneys during treatment (either a xanthine oxidase inhibitor or rasburicase — confirm with trial site).

Who may not be able to join:

• People whose CLL/SLL has already worsened or progressed while on BTK inhibitor therapy before the study begins.
• People who have previously received a combination of a BTK inhibitor together with venetoclax.
• People who have a history of their CLL transforming into a more aggressive cancer (Richter's transformation) or a related condition called prolymphocytic leukaemia.
• People with active Hepatitis B virus (HBV) infection where the virus is still detectable in the blood (people on suppressive therapy with an undetectable viral load may still be considered — confirm with trial site).
• People with a history of Hepatitis C virus (HCV) infection unless they have been treated and the virus is no longer detectable.
• People with severe heart failure (Class III or IV), unstable chest pain (angina), or uncontrolled irregular heartbeat.
• People currently taking blood-thinning medications such as heparin or warfarin (those on warfarin must stop taking it at least 10 days before joining — confirm with trial site).
• People taking certain medications that strongly affect how the body processes drugs (strong CYP3A4/5 inhibitors or inducers), unless the medication can be stopped at least 14 days before enrolment or the study team approves an exception.
• People who require more than a low daily dose of steroid medication (more than 20 mg of prednisone or equivalent per day).
• People who have an active, serious infection that currently requires intravenous (IV) antibiotics.

Important: Always verify eligibility with the trial site directly before applying.